NEJM evidenceAgedFemaleHumansMaleMiddle Aged
Cardiac Effects of Dapagliflozin in People with Chronic Kidney Disease.
Katja Vu Bartholdy, Niklas Dyrby Johansen, Kristoffer Grundtvig Skaarup, Daniel Modin, Nino Landler, Adam Femerling Langhoff, Camilla Ikast Ottosen, Caroline Espersen, Maria Dons, Julie Inge Marie Borchsenius, Lise Witten Davodian, Mats Højbjerg Lassen, Filip Soeskov Davidovski, Anne Marie Reimer Jensen, Morten Sengeløv
Published: 202510.1056/EVIDoa2500158
Abstract
BACKGROUND: Adverse cardiac remodeling is common in people with chronic kidney disease and contributes to increased cardiovascular risk. Although sodium-glucose cotransporter 2 (SGLT2) inhibitors have shown cardioprotective effects in patients with c…
Preview only. Read the full abstract at the source